Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Maravai LifeSciences Holdings, Inc. Class A Common Stock

MRVI

Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.

Last trade $7.28
Day change -$0.125 (-1.69%)
Day range $7.17 – $7.53
Volume 535,801
Market cap $1.10B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.1B
Price / earnings
—
Price / book
5.64×
Price / sales
5.19×
EV / sales
5.67×
EV / EBITDA
-176.88×

Profitability

Earnings per share
-$0.44
Return on assets
-10.94%
Return on equity
-33.52%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.9×
Current ratio
4.66×
Quick ratio
3.35×
Cash ratio
2.21×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.54M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for MRVI, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$45.85M$51.44M$65.84M$49.87M$41.63M$47.4M$46.85M$56.56M
Cost of revenue$29.66M$30.79M$32.14M$37.02M$35.98M$39.63M$39.13M$37.17M
Gross profit$16.19M$20.65M$33.7M$12.84M$5.66M$7.77M$7.73M$19.39M
Selling, general and administrative$30.5M$32.07M$29.09M$31.58M$35.46M$38.72M$39.56M$41.24M
Research and development$3.39M$3.7M$3.89M$3.79M$3.84M$4.88M$4.89M$4.56M
Total operating expenses$36.81M$35.74M$35.86M$71.64M$46.69M$74.05M$56.89M$57.09M
Operating income-$20.62M-$15.09M-$2.16M-$58.8M-$41.03M-$66.28M-$49.16M-$37.7M
Interest expense-$4.03M-$4.81M-$5.75M-$6.56M-$6.84M-$6.82M-$6.78M-$11.26M
Income before taxes-$24.08M-$21.8M-$6.53M-$63.01M-$45.15M-$74.13M-$52.69M-$46.07M
Income taxes-$75K-$171K-$151K$6K-$92K-$4.29M$162K-$7K
Net income-$24M-$21.63M-$6.38M-$63.02M-$45.06M-$69.84M-$52.85M-$46.07M
Net income attributable to common shareholders-$13.84M-$12.42M-$3.73M-$35.68M-$25.56M-$39.59M-$29.95M-$25.91M
EBITDA-$5.5M-$3.34M$12.09M-$10.08M-$20.46M-$22.67M-$24M-$13.42M
Basic earnings per share-$0.09-$0.08-$0.02-$0.25-$0.18-$0.27-$0.21-$0.18
Diluted earnings per share-$0.09-$0.08-$0.02-$0.25-$0.18-$0.27-$0.21-$0.18

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q3 Loss, Beats Revenue Estimates

Maravai LifeSciences reported a Q3 loss of $0.03 per share, beating the consensus estimate of $0.05 loss, with a 40% earnings surprise. Revenue of $45.85 million exceeded estimates by 6.66%, up from $41.63 million year-over-year. The stock has gained 129.2% year-to-date but carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.